Major Events - Minglue Technology (02718) plans to offer 7.219 million Class A shares globally from October 23 to October 28, with cornerstone subscriptions amounting to $59 million [1] - Wisco Properties (00230) received a privatization offer from Wisco Hong Kong at a premium of approximately 104.08%, with trading resuming on October 24 [1] - Junyu Foundation (01757) was acquired by China Venture Capital Holdings for 75% of its shares at a discount of about 79.06%, with trading resuming on October 24 [1] - Kangda Foods (00834) was acquired by Gaosi Shi for approximately 54.69% of the company’s shares at a premium of about 16.23%, with trading resuming on October 24 [1] - Hutchison China MediTech (00013) presented data on HMPL-A251 at the AACR-NCI-EORTC International Conference on Molecular Targeted and Cancer Therapeutics [1] - Giant Bio (02367) received a medical device registration certificate for its Type I α1 collagen lyophilized fiber product [1] - Yiming Anke-B (01541) completed the first patient dosing in the Phase IB/II clinical trial of IMM2510 combined with IMM01 [1] - Heng Rui Medicine (01276) received approval to conduct clinical trials for injection of Rikan Trastuzumab [1] - Hansoh Pharmaceutical (03692) had its application for HS-10365 capsule marketing approval accepted by the National Medical Products Administration [1] - Baixin An-B (02185) completed market access and the first commercial surgery for the IBERIS® RDN system in Switzerland [1] - Haotian International Construction Investment (01341) purchased a total of 646 units of Ethereum as of October 23 [1] Share Buybacks/Reductions - Cornerstone Pharmaceuticals-B (02616) saw CEO Yang Jianxin and senior management purchase an additional 1 million shares [2] - Midea Group (00300) repurchased 1.3434 million A shares for approximately 99.998 million yuan on October 23 [2] - China Communications Construction (01800) repurchased 119.45 million A shares for approximately 10.5994 million yuan on October 23 [2] - Mengniu Dairy (02319) repurchased 700,000 shares for approximately 10.0692 million HKD on October 23 [2] - Lianlian Digital (02598) spent about 7.5555 million HKD to repurchase 967,000 shares on October 23 [2] - Lianyi Rong Technology-W (09959) repurchased 2.47 million shares for approximately 7.4137 million HKD on October 23 [2] - Heng Rui Medicine (01276) repurchased 97,500 A shares for approximately 6.2808 million yuan on October 23 [2] - Gushengtang (02273) repurchased 19,860 shares for approximately 5.8634 million HKD on October 23 [2] Operating Performance - Ping An Good Doctor (01833) reported total revenue of approximately 3.725 billion yuan for the first three quarters, a year-on-year increase of 13.6%, and plans to continue expanding AI technology to enhance medical service efficiency and quality [2] - Sands China Ltd. (01928) reported a 7.5% year-on-year increase in net revenue to $1.9 billion for the third quarter [2] - Livzon Pharmaceutical (01513) announced a net profit attributable to shareholders of 1.754 billion yuan for the first three quarters, a year-on-year increase of 4.86% [2] - China Railway Construction (01186) signed new contracts totaling 1.518765 trillion yuan in the first three quarters, a year-on-year increase of 3.08% [2] - Prada (01913) reported net revenue of 4.07 billion euros for the first three quarters, a year-on-year increase of 9% [2] Additional Performance Metrics - Baio Family Interactive (02100) reported 10.2 million active accounts in the third quarter, a year-on-year increase of 37.8% [3] - Anton Oilfield Services (03337) secured new orders worth 1.273 billion yuan in the third quarter [3]

Core Points - The company Gushengtang has been actively repurchasing its shares, with a total of 482,530 shares bought back since September 10, amounting to HKD 151 million [2][3] - The stock price has seen a decline of 11.02% during the repurchase period, with the latest closing price at HKD 29.620, down 1.73% on the day of the latest buyback [2][3] - Year-to-date, Gushengtang has conducted 53 repurchase transactions, totaling 777,990 shares and an expenditure of HKD 245 million [2][3] Repurchase Details - On October 23, Gushengtang repurchased 198,600 shares at a price range of HKD 29.240 to HKD 29.800, with a total expenditure of HKD 5.8634 million [2] - The highest repurchase price during the recent buyback was HKD 30.200 on October 22, while the lowest was HKD 29.240 on October 23 [2] - The company has consistently repurchased shares over the past 30 days, indicating a strong commitment to supporting its stock price [2][3]

固生堂(02273)发布公告，于2025年10月23日，该公司斥资586.34万港元回购19.86万股。 ...

Group 1 - The company, Guoshengtang (02273.HK), announced a share buyback plan to repurchase 199,000 shares at a total cost of HKD 5.86 million [1] - The buyback will occur on October 23, 2025, with the repurchase price ranging from HKD 29.24 to HKD 29.80 per share [1]

智通财经APP讯，固生堂(02273)发布公告，于2025年10月23日，该公司斥资586.34万港元回购19.86万 股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 | 13). | 購回股份（擬註銷但尚未註銷） | | 240,000 | 0.1017 % | HKD | 31.7036 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年9月23日 | | | | | | 14). | 購回股份（擬註銷但尚未註銷） | | 150,000 | 0.0636 % | HKD | 31.3359 | | | 變動日期 | 2025年9月24日 | | | | | | 15). | 購回股份（擬註銷但尚未註銷） | | 140,000 | 0.0593 % | HKD | 31.2967 | | | 變動日期 | 2025年9月25日 | | | | | | 16). | 購回股份（擬註銷但尚未註銷） | | 100,000 | 0.0424 % | HKD | 30.6404 | | | 變動日期 | 2025年9月26日 | | | | | | 17). | 購回股份（擬註銷但尚未 ...

Core Viewpoint - The strategic partnership between Guoshengtang and Singapore's 1doc aims to integrate Traditional Chinese Medicine (TCM) into the mainstream medical system in Singapore, marking a significant milestone for the internationalization of TCM [1][4]. Group 1: Partnership Details - Guoshengtang and 1doc will systematically introduce TCM services in Western medical family clinics in Singapore, providing a collaborative healthcare experience that covers clinical diagnosis, daily health care, and community health [1][3]. - The partnership will involve a shareholding structure where Guoshengtang holds 70% and 1doc holds 30%, ensuring deep integration and professional operation of TCM services within Western medical settings [3][4]. - Patients will benefit from a comprehensive healthcare management approach that includes prevention, diagnosis, and rehabilitation, facilitated by TCM practitioners who can prescribe necessary tests to enhance diagnostic accuracy [3][4]. Group 2: Policy and Market Context - The Singapore government has been actively promoting the integration of TCM and Western medicine, exemplified by the "TCM Integration Sandbox Program" set to launch in 2025, which will test and evaluate TCM treatment plans in public healthcare institutions [4][5]. - 1doc, a subsidiary of IHG, operates a network of clinics in Singapore and has served over 79,000 patients, providing a strong local medical network and digital technology support for the implementation of TCM [4][5]. - Guoshengtang, as China's first publicly listed TCM chain, has established over 80 medical institutions in China and Singapore, serving more than 20 million customers and accumulating extensive clinical data to support the efficacy and safety of TCM [4][5]. Group 3: Future Prospects - The collaboration aims to create a "New TCM" service model in Singapore, exploring more partnership models to build a new ecosystem of collaborative diagnosis and treatment [5]. - The innovative policies and market openness in Singapore provide a high-standard international testing ground for Guoshengtang, with potential for replicating successful models in Southeast Asia and globally [5].

Core Viewpoint - The strategic partnership between Guoshengtang and Singapore's 1doc marks a significant milestone in integrating Traditional Chinese Medicine (TCM) into Singapore's mainstream healthcare system, promoting the internationalization of TCM [1][4]. Group 1: Partnership Details - Guoshengtang and 1doc will systematically introduce TCM services in Western medical family clinics in Singapore, providing a collaborative healthcare experience that covers clinical diagnosis, daily health care, and community health [1][3]. - The partnership structure involves Guoshengtang holding 70% and 1doc holding 30% of the TCM operations, ensuring deep integration and professional management of TCM services within Western medical settings [3][4]. - Patients will benefit from a comprehensive health management approach that includes prevention, diagnosis, and rehabilitation, facilitated by TCM practitioners who can prescribe necessary tests to enhance diagnostic accuracy [3][4]. Group 2: Policy and Market Context - The Singapore government has been actively promoting the integration of TCM and Western medicine, exemplified by the "TCM Integration Sandbox Program" set to launch in 2025, which will test and evaluate TCM treatment plans in public healthcare institutions [4][5]. - 1doc, a subsidiary of IHG, operates a robust network of clinics in Singapore, leveraging advanced technologies to support personalized and preventive healthcare, which will aid in the implementation of TCM services [4][5]. - Guoshengtang, as China's first publicly listed TCM chain, has established over 80 medical institutions in China and Singapore, serving more than 20 million patients, and has accumulated extensive clinical data to support the efficacy and safety of TCM [4][5]. Group 3: Future Prospects - The collaboration aims to create a "New TCM" service model in Singapore, exploring more partnership models to build a new ecosystem of collaborative diagnosis and treatment [5]. - Singapore's innovative policies and market openness provide a high-standard international testing ground for Guoshengtang, with potential for replicating successful models in Southeast Asia and globally [5].

Core Viewpoint - The strategic partnership between Gu Shengtang and 1doc marks a significant milestone for the integration of Traditional Chinese Medicine (TCM) into Singapore's mainstream healthcare system, promoting the internationalization of TCM [1][4]. Group 1: Partnership Details - Gu Shengtang and 1doc will systematically introduce TCM services in Western medical family clinics in Singapore, providing a collaborative healthcare experience that covers clinical diagnosis, daily health care, and community health [1][3]. - The partnership structure involves Gu Shengtang holding 70% of the shares and fully managing operations, while 1doc holds 30%, ensuring deep integration and professional operation of TCM services within Western medical settings [3][4]. - Patients will benefit from a comprehensive health management approach that includes prevention, diagnosis, and rehabilitation, facilitated by TCM practitioners who can prescribe necessary tests to enhance diagnostic accuracy [3][4]. Group 2: Supportive Environment - The Singaporean government actively promotes the integration of TCM and Western medicine, exemplified by the "TCM Integration Sandbox Program" set to launch in 2025, which will test and evaluate TCM treatment plans in public healthcare institutions [4]. - 1doc, a subsidiary of IHG, operates a robust network of clinics in Singapore, leveraging advanced digital technologies to support personalized and preventive healthcare, which will bolster the implementation of TCM [4][5]. - Gu Shengtang, as the first publicly listed TCM chain in China, has established over 80 medical institutions and served more than 20 million clients, providing a strong evidence base for the efficacy and safety of TCM [4][5]. Group 3: Future Prospects - The collaboration aims to create a "New TCM" service model in Singapore, representing Gu Shengtang's exploration of digital integration into international healthcare systems [5]. - Future plans include exploring more partnership models to build a collaborative healthcare ecosystem, promoting standardized and scalable development of TCM in international markets [5]. - Singapore's innovative policies and market openness provide a high-standard testing ground for Gu Shengtang, with potential for replicating successful models across Southeast Asia and globally [5].

Core Viewpoint - On October 22, 35 Hong Kong-listed companies conducted share buybacks, totaling 10.4965 million shares and an amount of 52.7745 million HKD [1][2]. Group 1: Buyback Details - The company with the highest buyback amount on October 22 was AAC Technologies, with a buyback amount of 11.9098 million HKD for 300,000 shares [1][2]. - Linklogis Technology-W followed with a buyback of 2.430 million shares, amounting to 7.4708 million HKD [1][2]. - Mengniu Dairy repurchased 500,000 shares for 7.1714 million HKD [1][2]. Group 2: Year-to-Date Buyback Totals - AAC Technologies has conducted multiple buybacks this year, with a cumulative buyback amount of 858.628 million HKD [2]. - Linklogis Technology-W's total buyback amount for the year reached 225.0668 million HKD [2]. - Mengniu Dairy's year-to-date buyback amount stands at 45.832 million HKD [2]. Group 3: Buyback Volume Rankings - The highest number of shares repurchased on October 22 was by Linklogis Technology-W, with 2.43 million shares [1][2]. - Other notable buybacks in terms of volume included MorningX Technology with 1.064 million shares and China Hengyou Group with 1 million shares [1][2].